Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2025
Event: Entry into a Material Definitive Agreement (Common Stock Purchase Agreement) with B. Riley Principal Capital II, LLC.
Key Financial Metrics and Transaction Terms
This filing details a financing facility rather than historical financial performance. Key metrics include:
- Facility Size: Up to $50,000,000 in aggregate gross purchase price for newly issued common stock.
- Term: 36 months from the Commencement Date.
- Pricing Mechanism: Volume Weighted Average Price (VWAP) less a fixed 3.0% discount.
- Issuance Cap (Exchange Cap): Limited to 19.99% of outstanding shares (3,904,374 shares) unless stockholder approval is obtained or the average purchase price equals or exceeds $7.56 per share.
- Beneficial Ownership Limit: B. Riley Principal Capital II cannot beneficially own more than 4.99% of outstanding shares.
- Cash Commitment Fee: Up to $500,000 (1.0% of total commitment), payable via 10% withholding from purchase proceeds.
- Legal Fees: Reimbursement up to $100,000 upon execution plus $5,000 per fiscal quarter.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Operational Impact
The filing represents a new source of potential liquidity. The Company retains sole discretion over the timing and amount of any sales; there is no obligation to sell shares. The agreement prohibits the Company from entering into other "Variable Rate Transactions" (e.g., other equity lines of credit or at-the-market offerings) during the term.
Guidance, Risks, and Contingencies
- Going Concern Risk: Management explicitly states that the Company's financial condition raises "substantial doubt as to its ability to continue as a going concern."
- Capital Needs: The Company requires substantial additional capital to finance operations; failure to obtain this capital could force delays or termination of development programs.
- Uncertainty of Proceeds: Actual proceeds depend on market conditions and the Company's election to sell; no sales are guaranteed.
- Termination: The agreement terminates automatically after 36 months, upon reaching the $50M cap, or if the stock is delisted. The Company may terminate at any time with 10 trading days' notice.
Investor Verification Checklist
- Verify the current cash balance and burn rate in the most recent 10-K or 10-Q to assess immediate liquidity needs.
- Confirm the current trading price relative to the $7.56 threshold required to bypass the 19.99% issuance cap.
- Review the "Risk Factors" section of the March 13, 2025 Form 10-K for detailed operational risks.
- Monitor future 8-K filings for the "Commencement Date" and the first execution of a Market Open or Intraday Purchase.
- Check for any stockholder approval votes required if the Company intends to issue shares exceeding the 19.99% cap at prices below $7.56.